India, Oct. 9 -- NATCO Pharma Limited announced a major legal victory enabling the launch of its generic version of Risdiplam, a drug used to treat Spinal Muscular Atrophy (SMA), a debilitating and often fatal disease in infants.
The decision follows the dismissal of an appeal by F. Hoffmann-La Roche AG by the Commercial Appellate Division of the Delhi High Court on October 9, 2025. Earlier, a Single Judge of the Delhi High Court, in a landmark judgment dated March 24, 2025, had denied Roche's plea for an injunction against NATCO, considering the patent's invalidity and emphasizing public interest, given the high pricing of the drug by Roche that made it largely inaccessible in India.
With the Division Bench now refusing Roche's appeal, t...